Immediate release abuse-deterrent granulated dosage forms
Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
1. An immediate release abuse deterrent dosage form comprising:
a) core-shell particles, the core-shell particles comprising:
a core, the core comprising a gelling polymer and a wax,
wherein the gelling polymer in the core is selected from ethylcellulose, aminoalkyl methacrylate copolymer, hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, polyethylene oxide, and combinations thereof;
wherein the core does not contain a sugar sphere or microcrystalline cellulose sphere;
an active pharmaceutical layer surrounding the core, the active pharmaceutical layer comprising an active pharmaceutical ingredient (API) that is a narcotic analgesic;
at least one layer surrounding the active pharmaceutical layer, the at least one layer comprising a pH-sensitive film comprising pH-sensitive polymer that is insoluble in water at a pH greater than 5 and is soluble in water at a pH below 5; and
b) a matrix comprising a disintegrant and a gelling polymer; wherein the gelling polymer in the matrix is selected from ethylcellulose, aminoalkyl methacrylate copolymer, hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, polyethylene oxide, and combinations thereof;
wherein the dosage form demonstrates an immediate release profile when administered in therapeutic doses, but demonstrates an extended release profile when administered in supratherapeutic doses, wherein a supratherapeutic dose refers to administering multiple individual dose units simultaneously; and
wherein the immediate release profile is defined as not less than 75% of API released in 30 minutes, and the extended release profile is defined as not more than 95% released in 60 minutes, wherein the release profiles may be evaluated by dissolution in 300 mL of 0.1N HCl media using USP II apparatus at 50 RPM paddle speed and 37° C.
2. The immediate release abuse deterrent dosage form according to claim 1 , wherein less than 5 weight percent of the total amount of the narcotic analgesic in the core shell particles is contained in the core.
3. The immediate release abuse deterrent dosage form according to claim 1 , wherein at least 90 percent of the total amount of the narcotic analgesic in the core shell particles is contained in the active pharmaceutical layer.
4. The immediate release abuse deterrent dosage form according to claim 1 , further comprising a second type of core-shell particles that do not contain an active pharmaceutical layer, the second type of core-shell particles comprising:
a core, the core comprising a gelling polymer, wherein the gelling polymer in the core is selected from hydroxypropyl methyl cellulose, hydroxy methyl cellulose, methyl cellulose, hydroxyethylmethyl cellulose, sodium carboxymethyl cellulose, a carbomer polymer, polyethylene oxide, polyvinyl alcohol and combinations thereof; and
at least one layer surrounding the core, the at least one layer comprising a pH-sensitive film comprising pH-sensitive polymer that is insoluble at a pH greater than 5 and is soluble at a pH below 5.
5. The immediate release abuse deterrent dosage form according to claim 1 , wherein the narcotic analgesic is an opioid.
6. The immediate release abuse deterrent dosage form according to claim 5 , further comprising a nonsteroidal analgesic drug.
7. The immediate release abuse deterrent dosage form according to claim 5 , wherein the opioid is selected from buprenorphine, codeine, dihydrocodeine, dihydromorphine, hydrocodone, hydromorphone, morphine, oxycodone, oxymorphone, and pharmaceutically acceptable salts thereof.
8. The immediate release abuse deterrent dosage form according to claim 6 , wherein the nonsteroidal analgesic drug is selected from acetaminophen, aspirin, ibuprofen and naproxen.
9. The immediate release abuse deterrent dosage form according to claim 1 , wherein the gelling polymer in the core comprises hydroxypropyl methyl cellulose.
10. The immediate release abuse deterrent dosage form according to claim 1 , wherein the gelling polymer in the core is present in an amount from 0.5 to 15 weight percent based on the total weight of the dosage form.
11. The immediate release abuse deterrent dosage form according to claim 1 , wherein the gelling polymer in the matrix comprises a carbomer polymer.
12. The immediate release abuse deterrent dosage form according to claim 1 , wherein the gelling polymer in the matrix is present in an amount from 0.5 to 15 weight percent based on the total weight of the dosage form.
13. The immediate release abuse deterrent dosage form according to claim 1 , wherein the disintegrant in the matrix is selected from corn starch, croscarmellose sodium, crospovidone, sodium starch glycolate, and combinations thereof.
14. The immediate release abuse deterrent dosage form according to claim 13 , wherein the dosage form comprises from 0.5 to 50 weight percent disintegrant based on total weight of the dosage form.
15. The immediate release abuse deterrent dosage form according to claim 1 , wherein the pH-sensitive polymer is a copolymer of dimethyl aminoethyl methacrylate, butyl methacrylate, and methyl methacrylate monomers.
16. The immediate release abuse deterrent dosage form according to claim 1 , wherein the dosage form excludes an emetic, a nasal irritant, an opioid antagonist, and an effervescent.
17. The dosage form according to claim 1 , wherein the dosage form, if ground and combined with a small volume of a solvent selected from ethanol, methanol, water, or a mixture thereof forms a composition having a viscosity that prevents uptake of the composition by a hypodermic syringe.
18. The dosage form according to claim 1 , wherein the dosage form reduces the risk of an overdose of the narcotic analgesic by simultaneous oral ingestion of multiple units of the oral dosage form.
19. The dosage form according to claim 1 , wherein the dosage form reduces the potential for abuse by simultaneous oral ingestion of multiple units of the oral dosage form.
20. The immediate release abuse deterrent dosage form according to claim 1 , wherein the supratherapeutic dose is five or more tablets.
21. The immediate release abuse deterrent dosage form according to claim 1 , wherein the dosage form is in a suppository, capsule, caplet, pill, gel, soft gelatin capsule, or compressed tablet form.
22. The immediate release abuse deterrent dosage form according to claim 21 , wherein the dosage form is in a compressed tablet form.
23. A method of alleviating, or ameliorating a level of pain in a subject, the method comprising administering to the subject a dosage form as recited at claim 1 .
24. A method of deterring abuse of a narcotic analgesic drug comprising providing an immediate release abuse deterrent dosage form according to claim 1 .
25. A method of reducing the risk of overdose by accidental or intentional administration of a supratherapeutic dose of a narcotic analgesic drug, comprising providing an immediate release abuse deterrent dosage form according to claim 1 .
26. The immediate release abuse deterrent dosage form according to claim 1 , wherein the wax in the core is selected from fatty acid esters, glycerol fatty acid esters, fatty alcohols and combinations thereof.